Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin

Neurochemistry International

Volumn 28, Issue 1, 1996, Pages 41-49

  Gerlach, M ^a,b   Gotz M ^a   Dirr, A ^a   Kupsch, A ^c,d   Janetzky, B ^a   Oertel, W ^d   Sautter, J ^c   Schwarz, J ^d   Reichmann, H ^a   Riederer, P ^a,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; FEMALE; MALE; MARMOSET; MITOCHONDRION; NERVE ENDING; NEUROPATHY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSONISM; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; PUTAMEN; RESPIRATORY CHAIN; SUBSTANTIA NIGRA; SYNAPSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMAL; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; CALLITHRIX; DOPAMINE AGENTS; FEMALE; MALE; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; SUPPORT, NON-U.S. GOV'T;

EID: 0029656203     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-0186(95)00063-E     Document Type: Article

References (60)

1. Aberg F., Appelkvist E. -L., Daliner G. and Ernster L. (1992) Distribution and redox state of ubiquinones in rat and human tissue. Archs Biochem. Biophys. 295, 230-234.
2. Adams J. D. and Odunze I. N. (1991) Biochemical mechanisms of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain? Biochem. Pharmac. 41, 1099-1105.
3. Adams J. D., Klaidman L. K. and Odunze I. N. (1989) Oxidative effects of MPTP in the midbrain. Res. Commun. Subs. Abuse 10, 169-180.
4. + induced oxygen radical formation with mitochondrial enzymes. Free Rad. Biol. Med. 15, 181-186.
5. Albanese A., Granata R., Gregori B., Piccardi M. P., Colsimo C. and Tonali P. (1993) Chronic administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. Neuroscience 55, 823-832.
6. Bates T. E., Heales S. J. R., Davies E. E. C., Boakye P. and Clark J. B. (1994) Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria : evidence for a primary involvement of energy depletion. J. Neurochem. 63, 640-648.
7. Bradford M. M. (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72, 248-254.
8. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M. and Kopin I. J. (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 80, 4546-4550.
9. Chan P., DeLanney L. E., Irwin I., Langston J. W. and Di Monte D. (1991) Rapid ATP loss caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mouse brain. J. Neurochem. 57, 348-351.
10. Chiueh C. C., Miyake H. and Peng M. T. (1993) Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanism involved in MPTP-induced parkinsonism. Adv. Neurol. 60, 251-258.
11. Cleeter M. W., Cooper J. M. and Schapira A. H. (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58, 786-789.
12. Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Caine C. D., Reichert C. M. and Kopin I. J. (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res. 1, 249-254.
13. Di Monte D. A., Chan, P. and Sandy S. M. (1992) Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage. Ann. Neurol. 32, 111-115.
14. Ernster L. and Forsmark-Andrée P. (1993) Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin. Invest. 71, 60-65.
15. Fariello R. G., Ghirardi O., Peschechera A., Ramacci M. T. and Angelucci L. (1987). Transient nigral ubiquinone depletion after single MPTP administration in mice. Neuropharmacology 26, 1799-1802.
16. Gerlach M., Riederer P., Przuntek H. and Youdim M. B. H. (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmac. (Molec. Pharmac. Sect.) 208, 273-286.
17. Gerlach M., Ben-Shachar D., Riederer P. and Youdim M. B. H. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807.
18. Götz M. E., Dirr A., Freyberger A., Burger R. and Riederer P. (1993) The thiobarbituric acid reflects susceptibility to oxygen induced lipid peroxidation in vitro rather than levels of lipid hydroperoxides in vivo: a methodological approach. Neurochem. Int. 22, 255-262.
19. Götz M. E., Dirr A., Burger R., Janetzky B., Weinmüller M., Chan W. W., Chen S. C., Reichmann H., Rausch W. -D. and Riederer P. (1994a) Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrdine and diethyl-dithiocarbamate. Eur. J. Pharmac. (Molec. Pharmac. Sect.) 266, 291-300.
20. Götz M. E., Künig G., Riederer P. and Youdim M. B. H. (1994b). Oxidative stress : free radical production in neural degeneration. Pharmac. Ther. 63, 37-122.
21. Halliwell B. (1992). Reactive oxygen species and the central nervous system J. Neurochem. 59, 1609-1623.
22. Heales S. J. R., Davies S. E. C., Bates T. E. and Clark J. B. (1995). Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem. Res. 20, 31-38.
23. Heikkila R. E., Sieber B.-A., Manzino L. and Sonsalla P. K. (1989). Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Molec. Chem. Neuropath. 10, 171-183.
24. Jenner P., Rupniak N. M. J., Rose S., Kelly E., Kilpatrick G., Lees L. and Marsden, C. D. (1984). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in the common marmoset. Neurosci. Lett. 50, 85-90.
25. +) within catecholaminergic neurons. Neurotoxicology 12, 285-302.
26. Kinemuchi H., Fowler C. J. and Tipton K. F. (1987). The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease. Neurochem. Int. 11, 359-373.
27. King T. E. and Howard R. L. (1967). Preparation and properties of soluble NADH dehydrogenase from cardiac muscle. Meth. Enzym. 10, 275-294.
28. Krien P. M., Margon V. and Kermici M. (1992). Electrochemical determination of femtomole amounts of free reduced and oxidized glutathione. J. Chromatogr. 576, 255-261.
29. Langston J. W., Forno L. S., Rebert C. S. and Irwin I. (1984). Selective nigral toxicity after administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292, 390-394.
30. Marzatico F., Café C., Taborelli M. and Benzi G. (1993). Experimental Parkinson's disease in monkeys. Effect of ergort alkaloid derivative on lipid peroxidation in different brain areas. Neurochem. Res. 18, 1101-1106.
31. McGeer P. L., Sir Eccles J. C. and McGeer E. G. (1987). Molecular Neurobiology of the Mammalian Brain, 2nd edition, p. 24. Plenum Press, New York.
32. Mithöfer K., Sandy M. S., Smith M. T. and Di Lonte D. (1992). Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Archs Biochem. Biophys. 295, 132-136.
33. Mizuno Y., Sone N. and Saitoh T. (1987). Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 48, 1787-1793.
34. Mizuno Y., Susuki K., Sone N. and Saitoh T. (1988). Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain in vivo. Neurosci. Lett. 91, 349-353.
35. Nakamura H., Kato S. and Tanaka J. (1989). Mitochondria covered with a net of parallel and latticed filaments in nigral neurons of monkeys with experimental parkinsonism. Acta Neuropath. 77, 489-493.
36. Nicklas W. J., Vyas I. and Heikkila R. E. (1985). Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36, 2503-2508.
37. +. J. Neural Transm. (Gen.Sect.) 89, 139-145.
38. Oishi T., Hasegawa E. and Murai Y. (1993). Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. J. Neural Transm. (P.-D.Sect.) 6, 45-52.
39. Pette D. and Reichmann H. (1982). A method for quantitative extraction of enzymes and metabolites from tissue samples in the milligram range. J. Histochem. Cytochem. 30, 401-402.
40. +, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Archs Biochem. Biophys. 259, 645-649.
41. Reichmann H., Hoppeler H., Matthieu-Costello O., von Bergen F. and Pette D. (1985) Biochemical and structural changes of skeletal muscle mitochondria after chronic electrical stimulation in rabbits. Pflügers Arch. 404, 1-9.
42. Reichmann H., Lestienne P., Jellinger K. and Riederer P. (1993) Parkinson's disease and the electron transport chain in post mortem brain. In Advances in Neurology, (Narabayashi H., Nagatsu T., Yanagisawa N. and Mizuno Y., eds), Vol. 60, pp. 297-299. Raven Press, New York.
43. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G. P., Jellinger K. and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
44. Russ H., Mihatsch W., Gerlach M., Riederer P. and Przuntek H. (1991) Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neurosci. Lett. 123, 115-118.
45. Sauer H., Frodl E. M., Kupsch A., ten Bruggencate G. and Oertel W. H. (1992) Effects of cryopreservation on survival and function of intrastriatal fetal mesencephalic grafts. Exp. Brain Res. 90, 54-62.
46. Sayre L. M. (1989) Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxic. Lett. 48, 121-149.
47. Schapira A. H. V. (1994) Review: evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov. Disord. 9, 125-138.
48. Schapira A. H. V., Cooper J., Dexter D., Clark J. B., Jenner P. and Marsden C. D. (1990). Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
49. Slivka A., Spina M. B. and Cohen G. (1987) Reduced and oxidized glutathione in human and monkey brain. Neurosci. Lett. 74, 112-118.
50. Sofic E., Lange K. W., Jellinger K. and Riederer P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142, 128-130.
51. Stephen H., Baron G. and Schwerdtfeger W. K. (1980) The Brain of the Common Marmoset (Callithrix jacchus) - A Stereotactic Atlas. Springer, Vienna.
52. Storey E., Hyman B. T., Jenkins B., Brouillet E., Miller J. M., Rosen B. R. and Beal M. F. (1992) 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58, 1975-1978.
53. Tipton K. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
54. Villa R. F., Arnaboldi R., Ghigini B. and Gorini A. (1992) Mitochondrial factors involved in Parkinson's disease by MPTP toxicity in Macaca fascicularis and drug effect. Neurochem. Res. 17, 1147-1154.
55. Wagner J., Vitali P., Palfreyman M. G., Zraika M. and Hout S. (1982) Simultaneous determination of 3,4,-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindole acetic acid in rat cerebrospinal fluid and brain by high performance liquid chromatography with electrochemical detection. J. Neurochem. 38, 1241-1254.
56. Werner P. and Cohen G. (1991) Intramitochondrial formation of oxidized glutathione during the oxidation of benzylamine by monoamine oxidase. FEBS Lett. 280, 44-46.
57. Wilcoxon F. (1945) Individual comparisons by ranking methods. Biometrics 1, 80-83.
58. Wüllner U., Kupsch A., Arnold G., Renner P., Scheid C., Oertel W. and Klockgether T. (1992) The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets. Neuropharmacology 31, 713-715.
59. Youdim M. B. H., Ben-Shachar D., Eshel G., Finberg J. P. M. and Riederer P. (1993) The neurotoxicity of iron and nitric oxide: relevance to the etiology of Parkinson's disease. In Advances in Neurology, (Narabayashi H., Nagatsu T., Yanagisawa N. and Mizuno Y., eds), Vol. 60, pp. 259-266. Raven Press, New York.
60. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F. and Corsini G. U. (1992) MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in primates. J. Neurochem. 59, 733-739.